Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay

Nucleic Acid Therapeutics

Volumn 27, Issue 6, 2017, Pages 323-334

  Godinho, Bruno M D C ^a   Gilbert, James W ^a   Haraszti, Reka A ^a   Coles, Andrew H ^a   Biscans, Annabelle ^a   Roux, Loic ^a   Nikan, Mehran ^a   Echeverria, Dimas ^a   Hassler, Matthew ^a   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

biodistribution; Pharmacokinetics; RNA interference; siRNA; therapeutic oligonucleotides

Indexed keywords

CHOLESTEROL; DOCOSAHEXAENOIC ACID; PEPTIDE NUCLEIC ACID; PHOSPHORYLCHOLINE; SMALL INTERFERING RNA; OLIGONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUC (0-48 H); BLOOD SAMPLING; BLOOD-TO-PLASMA RATIO; BRAIN REGION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; ELIMINATION HALF-LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; PLASMA CLEARANCE; PRIORITY JOURNAL; SAPHENOUS VEIN; SERIAL BLOOD MICROSAMPLING; SKIN BIOPSY; TISSUE DISTRIBUTION; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD; CHEMISTRY; HIGH THROUGHPUT SCREENING; INBRED MOUSE STRAIN; KIDNEY; LIVER; METABOLISM; PROCEDURES;

ANIMALS; CHOLESTEROL; DOCOSAHEXAENOIC ACIDS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; KIDNEY; LIVER; MICE; MICE, INBRED STRAINS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS; PHOSPHORYLCHOLINE; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 85035318115     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2017.0690     Document Type: Article

References (50)

1. Scherman D, A Rousseau, P Bigey and V Escriou. (2017). Genetic pharmacology: progresses in siRNA delivery and therapeutic applications. Gene Ther 24:151-156.
2. Khvorova A. (2017). Oligonucleotide therapeutics-a new class of cholesterol-lowering drugs. N Engl J Med 376:4-7.
3. Khvorova A, MF Osborn and MR Hassler. (2014). Taking charge of siRNA delivery. Nat Biotech 32:1197-1198.
4. Zimmermann TS, V Karsten, A Chan, J Chiesa, M Boyce, BR Bettencourt, R Hutabarat, S Nochur, A Vaishnaw and J Gollob. (2017). Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther 25:71-78.
5. Liu B, J Chang, WP Gordon, J Isbell, Y Zhou and T Tunt-land. (2008). Snapshot PK: a rapid rodent in vivo preclinical screening approach. Drug Discov Today 13:360-367.
6. Li C, B Liu, J Chang, T Groessl, M Zimmerman, Y-Q He, J Isbell and T Tuntland. (2013). A modern in vivo pharma-cokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery. Drug Discov Today 18:71-78.
7. Morrissey DV, JA Lockridge, L Shaw, K Blanchard, K Jensen, W Breen, K Hartsough, L Machemer, S Radka and V Jadhav. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007.
8. Solano EC, DJ Kornbrust, A Beaudry, JW-D Foy, DJ Schneider and JD Thompson. (2014). Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther 24:258-266.
9. Yu RZ, T-W Kim, A Hong, TA Watanabe, HJ Gaus and RS Geary. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oli-gonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460-468.
10. Bienk K, ML Hvam, MM Pakula, F Dagnæs-Hansen, J Wengel, BM Malle, U Kragh-Hansen, J Cameron, JT Bukrinski and KA Howard. (2016). An albumin-mediated cholesterol design-based strategy for tuning siRNA phar-macokinetics and gene silencing. J Control Release 232: 143-151.
11. Chen S, YYC Tam, PJ Lin, AK Leung, YK Tam and PR Cullis. (2014). Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release 196:106-112.
12. Huang Y, Q Cheng, J-L Ji, S Zheng, L Du, L Meng, Y Wu, D Zhao, X Wang and L Lai. (2016). Pharmacokinetic behaviors of intravenously administered siRNA in glandular tissues. Theranostics 6:1528.
13. Malhotra M, C Tomaro-Duchesneau, S Saha and S Prakash. (2013). Systemic siRNA delivery via peptide-tagged polymeric nanoparticles, targeting PLK1 gene in a mouse xe-nograft model of colorectal cancer. Int J Biomater 2013: 252531.
14. Kim E-J, TG Park, Y-K Oh and C-K Shim. (2010). Assessment of siRNA pharmacokinetics using ELISA-based quantification. J Control Release 143:80-87.
15. Lozac'h F, J Christensen, T Faller, E Kerkhof, J Krauser, M Garnier, K Litherland, A Catoire, F Natt and J Hunziker. (2016). ADME studies of [5-3H]-2¢-O-methyluridine nu-cleoside in mice: a building block in siRNA therapeutics. Pharmacol Res Perspect 4:e00209.
16. Van de Water FM, OC Boerman, AC Wouterse, JG Peters, FG Russel and R Masereeuw. (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34:1393-1397.
17. Christensen J, K Litherland, T Faller, E Van de Kerkhof, F Natt, J Hunziker, J Krauser and P Swart. (2013). Metabolism studies of unformulated internally [3H]-labeled short interfering RNAs in mice. Drug Metab Dispos 41:1211-1219.
18. Viel T, R Boisgard, B Kuhnast, B Jego, K Siquier-Pernet, F Hinnen, F Dolle and B Tavitian. (2008). Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs). Oligonucleo-tides 18:201-212.
19. Ly S, DM Navaroli, M-C Didiot, J Cardia, L Pandar-inathan, JF Alterman, K Fogarty, C Standley, LM Lifshitz, et al. (2017). Visualization of self-delivering hydro-phobically modified siRNA cellular internalization. Nucleic Acids Res 45:15-25.
20. Alterman JF, LM Hall, AH Coles, MR Hassler, M-C Di-diot, K Chase, J Abraham, E Sottosanti, E Johnson and E Sapp. (2015). Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol Ther Nucleic Acids 4:e266.
21. Geary RS, TA Watanabe, L Truong, S Freier, EA Lesnik, NB Sioufi, H Sasmor, M Manoharan and AA Levin. (2001). Pharmacokinetic properties of 2¢-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897.
22. Park J, J Park, Y Pei, J Xu and Y Yeo. (2016). Pharma-cokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev 104:93-109.
23. Yu RZ, MJ Graham, N Post, S Riney, T Zanardi, S Hall, J Burkey, CS Shemesh, TP Prakash and PP Seth. (2016). Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. Mol Ther Nucleic Acids 5:e317.
24. Yu RZ, R Gunawan, N Post, T Zanardi, S Hall, J Burkey, T-W Kim, MJ Graham, TP Prakash and PP Seth. (2016). Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys. Nucleic Acid Ther 26:372-380.
25. Rosie ZY, B Baker, A Chappell, RS Geary, E Cheung and AA Levin. (2002). Development of an ultrasensitive non-competitive hybridization-ligation enzyme-linked immu-nosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25.
26. Roehl I, M Schuster and S Seiffert. (2011). Oligonucleotide detection method. US Patent US20110201006A1:1-9.
27. Nikan M, MF Osborn, AH Coles, BM Godinho, LM Hall, RA Haraszti, MR Hassler, D Echeverria, N Aronin and A Khvorova. (2016). Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol Ther Nucleic Acids 5: e344.
28. Nikan M, MF Osborn, AH Coles, A Biscans, B Godinho, R Haraszti, E Sapp, D Echeverria, M DiFiglia and N Aronin. (2017). Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable, O-phosphocholine-N-docosahexaenoyl-L-serine siRNA conjugate in mouse brain. Bioconjug Chem 28:1758-1766.
29. Reynolds A, D Leake, Q Boese, S Scaringe, WS Marshall and A Khvorova. (2004). Rational siRNA design for RNA interference. Nat Biotechnol 22:326-330.
30. Peng SX, BA Rockafellow, TM Skedzielewski, ND Hue-bert and W Hageman. (2009). Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharm Sci 98:1877-1884.
31. Zhang Y, M Huo, J Zhou and S Xie. (2010). PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99:306-314.
32. Trubetskoy VS, JB Griffin, AL Nicholas, EM Nord, Z Xu, RM Peterson, CI Wooddell, DB Rozema, DH Wakefield, DL Lewis and SB Kanner. (2017). Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses. Nucleic Acids Res 45:1469-1478.
33. Tian Q, J Rogness, M Meng and Z Li. (2017). Quantitative determination of a siRNA (AD00370) in rat plasma using peptide nucleic acid probe and HPLC with fluorescence detection. Bioanalysis 9:861-872.
34. Haraszti RA, L Roux, AH Coles, AA Turanov, JF Alter-man, D Echeverria, BM Godinho, N Aronin and A Khvorova. (2017). 5¢-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res 45:7581-7592.
35. Järve A, J Müller, I-H Kim, K Rohr, C MacLean, G Fricker, U Massing, F Eberle, A Dalpke and R Fischer. (2007). Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Res 35:e124.
36. Harborth J, SM Elbashir, K Vandenburgh, H Manninga, SA Scaringe, K Weber and T Tuschl. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83-105.
37. Grünweller A, C Gillen, VA Erdmann and J Kurreck. (2003). Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1. Oli-gonucleotides 13:345-352.
38. Dunne J, B Drescher, H Riehle, P Hadwiger, BD Young, J Krauter and O Heidenreich. (2003). The apparent uptake of fluorescently labeled siRNAs by electroporated cells depends on the fluorochrome. Oligonucleotides 13:375-380.
39. Coles AH, MF Osborn, JF Alterman, AA Turanov, BM Godinho, L Kennington, K Chase, N Aronin and A Khvorova. (2016). A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene si-lencing in vivo. Nucleic Acid Ther 26:86-92.
40. Geary RS, D Norris, R Yu and CF Bennett. (2015). Phar-macokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46-51.
41. Geary RS. (2009). Antisense oligonucleotide pharmacoki-netics and metabolism. Expert Opin Drug Metab Toxicol 5:381-391.
42. Godinho BM, JR Ogier, A Quinlan, R Darcy, BT Griffin, JF Cryan and CM O'Driscoll. (2014). PEGylated cyclodex-trins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability. Int J Pharm 473:105-112.
43. Thompson JD, DJ Kornbrust, JW Foy, EC Solano, DJ Schneider, E Feinstein, BA Molitoris and S Erlich. (2012). Toxicological and pharmacokinetic properties of chemi-cally modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther 22:255-264.
44. Khvorova A and JK Watts. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Bio-technol 35:238-248.
45. Wolfrum C, S Shi, KN Jayaprakash, M Jayaraman, G Wang, RK Pandey, KG Rajeev, T Nakayama, K Charrise and EM Ndungo. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157.
46. Geary RS, ZY Rosie, T Watanabe, SP Henry, GE Hardee, A Chappell, J Matson, H Sasmor, L Cummins and AA Levin. (2003). Pharmacokinetics of a tumor necrosis factor-a phosphorothioate 2¢-O-(2-methoxyethyl) modified anti-sense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419-1428.
47. Prakash TP, MJ Graham, J Yu, R Carty, A Low, A Chap-pell, K Schmidt, C Zhao, M Aghajan and HF Murray. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42: 8796-8807.
48. Bortolozzi A, A Castañé, J Semakova, N Santana, G Alvarado, R Cortés, A Ferrés-Coy, G Fernández, MC Carmona and M Toth. (2012). Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol Psychiatry 17: 612-623.
49. Ferrés-Coy A, M Galofré, F Pilar-Cuéllar, R Vidal, V Paz, E Ruiz-Bronchal, L Campa, A Pazos, J Caso and J Leza. (2016). Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration. Mol Psychiatry 21: 328-338.
50. Penner N, LJ Klunk and C Prakash. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185-203.